Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Bayer plans sale of $2.5bn diabetes device business

Germany-based Bayer is, reportedly, planning to sell its diabetes device business, which could be valued at $2.5bn for the company.

People familiar with the matter were quoted by Bloomberg as saying that the company intends to sell the business unit, in a bid to focus on health sectors.

Credit Suisse Group is supporting the Bayer on the potential sale of the business and private-equity firms such as Cinven, EQT Partners, KKR & Co and Triton Advisers may bid for the unit, reports the news agency.

Reports also emerged that Bayer CEO Marijn Dekkers is divesting peripheral units to focus more on life-sciences businesses.

In May, the company agreed to acquire over-the-counter drug business from Merck for $14.2bn.

Representatives from the companies related to the deal declined to comment on the matter.